*Type of the Paper (This Word template contains the sections required for Original Research, Systematic Review, Meta-Analyses, etc.)*

**Title of the Manuscript**

Firstname Lastname1, Firstname Lastname2, Firstname Lastname1,\*

1Department, Institution, ZIP code City, State (if any), Country

2Department, Institution, City, State (Abbreviated format) ZIP code, Country

\*Correspondence: E-mail address (Firstname Lastname)

Tel (Optional): [Full international phone number]

Fax (optional): [Full international fax number.]

Email (mandatory)

†These authors contributed equally.

ORCID [We recommend that the author complete this optional field]:

Firstname Lastname: 0000-0002-2451-xxxx

Firstname Lastname: 0000-0002-2452-xxxx

Firstname Lastname: 0000-0002-2453-xxxx

**Title of the Manuscript**

Abstract

Original research, systematic reviews, and meta-analyses require structured abstracts. The abstract must include the following separate sections: **Background**: The context and purpose of the study; **Methods**: How the study was performed and statistical tests used; **Results**: Succinct presentation of key results; please include sample sizes throughout; **Conclusions**: Brief summary and potential implications; **Clinical Trial registration**: When applicable, include a fifth heading, “Clinical Trial Registration.” Please include the Unique Identifier and the URL of the publicly accessible website on which the trial is registered. If the data have been deposited in a public repository and/or are being used in a secondary analysis, authors should state at the end of the abstract the unique, persistent data set identifier; repository name; and number. (Should no more than 350 words) [Abbreviations should initially be introduced in the abstract and the main text, detailing their full form before usage]

Keywords

keyword 1; keyword 2; keyword 3; keyword 4 [List at least three but no more than ten pertinent keywords.]

# 1. Introduction [first level heading]

State the objectives of the work and provide an adequate background to clarify why the study was undertaken and what hypotheses were tested, avoiding a detailed literature survey or a summary of the results. The information in this section should always be referenced. Also, use the [numbers] for the references in the full text, e.g., [1] or [5, 6, 7] or [9–11]. [Abbreviations should initially be introduced in the abstract and the main text, detailing their full form before usage.]

# 2. Materials and Methods

The source of material used and relevant ethical framework for all experiments should be clearly identified (ethics approval and/or written informed consent). Methods already published should be indicated by a reference: only relevant modifications should be described. This implies that a full description of all the experiments described in Results and presented in the Figures/Tables is expected in this section. For each experiment, all steps need to be mentioned, along with instruments the analyses were performed on, reagents and methods to permit the replication of the work by others. We would encourage authors to submitting a detailed Bio-protocol.

# 3. Results

Include a concise summary of the data presented in all display items (figures and tables). Excessive elaboration of data shown in display items should be avoided. Numerical data should be analyzed using appropriate statistical tests described in the Experimental Design and Statistical Analysis section. Authors must provide detailed information for each statistical test applied. Report exact *p-*values rather than ranges (e.g., *p* = 0.048 rather than *p* < 0.05).

*3.1 Figures, Tables, Motions, and Equations, etc.* [second level heading]

All figures and tables should be cited in the main text as Fig. 1, Table 1, Eqn. 1, Motion 1, etc.

### 3.1.1 Figures [third level heading]

Provide figure images in JPG, TIF format; Color images must be in RGB mode (do not support CMKY mode). The suggested minimum resolution of image is 300 dpi. Figures should be placed in the main text near to the first time they are cited. Also, the legend should be detailed, it is not acceptable to give only one or two lines description of figures.



Fig. 1. Figure title. (A) Description of what is contained in the first subfigure. (B) Description of what is contained in the second subfigure. Abbreviations appear in a figure should be listed at here. Obtain permission and acknowledgement required by the copyright holder if a figure is being reproduced from another source.

### 3.1.2 Tables

Tables should be placed in the main text near to the first time they are cited.

Table 1. This is sample table caption.

|  |  |  |  |
| --- | --- | --- | --- |
| Title 1 | Title 2 | Title 3 | Title 4 |
| Entry 1 | data | data | data |
| Entry 2 | data | data | data |
| Entry 3 | data | data | data |
| Entry 4 | data | data | data |

Table footnotes.

### 3.1.3 Mathematical Components

This is the example 1 of equation [fourth level heading]

(1)

the text following an equation need not be a new paragraph. Please punctuate equations as regular text.

This is the example 2 of equation

(2)

The text following an equation if were a new paragraph, please punctuate equations as regular text.

*3.2 Units*

* A space should be inserted before measurement units: 17 mL, 17 mol/L, 17 cm.
* Capitalize the letter L in some units: mL, L.
* The letter p should be lowercase and in italic type: *p*, *p*-value.
* Decimal points should use a full stop (.) NOT a comma (,): 0.17, 10.375.

# 4. Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

# 5. Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section. However, if the article type is Original Research, there must be a Conclusions section, which should be distinguished from the Discussion section.

Abbreviations [optional section]

AAA, abdominal aortic aneurysm; AVF, arteriovenous fistula; IVC, inferior vena cava; CRRT, continuous renal replacement therapy; CT, computed tomography; ICU, intensive care unit; ALT, alanine transaminase; AST, aspartate transaminase; TBIL, total bilirubin; DBIL, direct bilirubin.

Supplementary Material [optional section]

Authors of accepted manuscripts may provide related supplemental data to be posted online along with the published manuscript. All Supplemental Data information (except videos) should be combined into a single Word/PDF file. Before submission, carefully review all files; if you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. The journal is not responsible for any errors contained in data supplements.

Appendix [optional section]

All appendix materials must be cited in the main text.

Availability of Data and Materials

This section is strongly encouraged that all datasets on which the conclusions of a manuscript depend should be available to readers, unless they are already provided as part of the submitted article. Authors who do not wish to share their data must state this fact, and also provide an explanation as to why the data are unavailable. More information about [Availability of Data and Materials Policy](https://www.imrpress.com/page/editorial-policies#availability_of_data_and_materials).

Example: The raw data of microscopic images of brain sections are deposited to Zenodo and will be publicly available as of the date of publication. All data reported in this paper will also be shared by the lead contact upon request.

Author Contributions

All authors must meet the 4 criteria for authorship as outlined in the [authorship policy](https://www.imrpress.com/journal/FBL/page/instructions#Authorship). Those who contributed to the work but do not meet the criteria for authorship can be mentioned in the Acknowledgments.

Example: Initials (Author A) and Initials (Author C) designed the research study. Initials (Author B) performed the research. Initials (Author D) provided help and advice on ... Initials (Author A) analyzed the data. Initials (Author B, C and D) wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

This section is required for all papers. Manuscripts reporting studies involving human participants, human data or human tissue must: include a statement on ethics approval and consent (even where the need for approval was waived) include the name of the ethics committee that approved the study and the committee’s reference number if appropriate. Studies involving animals must include a statement on ethics approval. If the article does not involve this part, please add: “Not applicable.” More information about [Ethics Approval and Consent to Participate Policies](https://www.imrpress.com/page/editorial-policies).

Example: The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the Ethics Committee of XXX (Ethic Approval Number: xxxxxx), and all of the participants provided signed informed consent.

Acknowledgment

This section is required for all papers. Here you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments). Please do not thank the editors in this section, but you can send an email to express thanks. More information about [Acknowledgment Policy](https://www.imrpress.com/page/editorial-policies#authorship).

Example: We gratefully acknowledge the assistance and instruction from professor XXX of the XXX Institute for XXX and the XXX Investigators.

Funding

This section is required for all papers. Please add: “This research received no external funding.” or “This research was funded by Name of Funder, grant number XXX.”

Conflict of Interest

This section is required for all papers. If there are no interests to declare, please add: “The authors declare no conflict of interest. More information about [Conflict of Interest Policy](https://www.imrpress.com/page/editorial-policies#conflict_of_interests).

Declaration of AI and AI-assisted Technologies in the Writing Process

In accordance with [COPE’s stated position](https://publicationethics.org/cope-position-statements/ai-author) on AI tools and [ICMJE’s authorship criteria](https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html), artificial intelligence chatbots, such as [ChatGPT](https://openai.com/index/chatgpt/) and similar AI tools based on large language models (LLMs), cannot be listed as an author of a paper. If the author(s) have used AI tools in drafting of the manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, the authors must be transparent concerning the use of AI tools. Furthermore, AI tool use must be disclosed in this section. Authors are fully responsible for the content of their manuscript, even those portions produced by an AI tool, and are thus liable for any breach of publication ethics. Final decisions concerning whether the use of an AI tool is appropriate, or permissible, in a submitted manuscript lies with the journals’ editors. Specifically, the Editor-in-Chief is responsible for decisions concerning regular journal submissions, or an Editorial Board member may be appointed by the Editor-in-Chief to make such judgements in the case of a conflict of interest or for other circumstances.

**Example:** During the preparation of this work the authors used ChatGpt-3.5 in order to check spell and grammar. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the publication.

References and Notes

Please note that authors are responsible for the accuracy and completeness of their [references](https://www.imrpress.com/page/editorial-policies#citations).

Sample reference citation ([Download EndNote style](https://storage.imrpress.com/IMR/1948300520956592000/application/EndNote-style.ens)).

[1] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Article title. Title of journal. Year; volume: pages. https://doi.org/...

[2] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Article title. Title of journal. Year; volume: pages. (In Language) https://doi.org/...

[3] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Book Title. Edition - if available. Publisher: City, Country. Year. https://doi.org/...

[4] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Title of chapter. In Surname of the editor(s) Initial(s) (ed(s).) Book title Page. Edition. Publisher: City, Country. Year. https://doi.org/...

[5] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. Title. Year. Available at: URL (Accessed: Day month year). https://doi.org/...

[6] Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), Surname Initial(s), *et al*. ‘Title of paper’, Title of the conference. Place and date of the conference. Publisher: City, Country. Year of Publication. https://doi.org/...

[7] The advantage of endnotes, is that they are all arranged sequentially in one place, regardless of the length of individual notes.